. . . . "-5"^^ . . . . . . . . "Fasoracetam"@en . . . . . . "Fasoracetam"@es . . . . . . . . . "Fasoracetam (NS-105, 5-oxo-D-prolinepiperidinamide monohydrate) es una sustancia qu\u00EDmica en investigaci\u00F3n de la familia de los racetam.\u200B Este nootropico est\u00E1 siendo estudiado para tratar el S\u00EDndrome de Atenci\u00F3n con hiperactividad y est\u00E1 en fase de pruebas desde 2015 arrojando resultados positivos.\u200B Es com\u00FAn como suplemento nutricional nootropico (que favorece las capacidades intelectuales), de venta por internet, as\u00ED como otros compuestos de la misma familia."@es . . "1047948152"^^ . "Fasoracetam is a research chemical of the racetam family. It is a putative nootropic that failed to show sufficient efficacy in clinical trials for vascular dementia. It is currently being studied for its potential use for attention deficit hyperactivity disorder. Fasoracetam appears to agonize all three groups of metabotropic glutamate receptors and has improved cognitive function in rodent studies. It is orally bioavailable and is excreted mostly unchanged via the urine. Fasoracetam was discovered by scientists at the Japanese pharmaceutical company , which brought it through Phase 3 clinical trials for vascular dementia, and abandoned it due to lack of efficacy. Scientists at Children's Hospital of Philadelphia led by Hakon Hakonarson have studied fasoracetam's potential use in attention deficit hyperactivity disorder. Hakonarson started a company called neuroFix Therapeutics to try to bring the drug to market for this use; neuroFix acquired Nippon Shinyaku's clinical data as part of its efforts. neuroFix was acquired by Medgenics in 2015. Medgenics changed its name to Aevi Genomic Medicine in 2016. Clinical trials in adolescents with ADHD who also have mGluR mutations started in 2016. While Fasoracetam may be effective in the treatment of ADHD in people with specific mGluR mutations, these represent around 10% of total ADHD cases, and Fasoracetam is likely ineffective in all other cases. Studies showing improvements in cognitive function from Fasoracetam have exclusively been done on rodents."@en . . . . . . . . . "\u30D5\u30A1\u30BD\u30E9\u30BB\u30BF\u30E0"@ja . . . . "Fasoracetam is a research chemical of the racetam family. It is a putative nootropic that failed to show sufficient efficacy in clinical trials for vascular dementia. It is currently being studied for its potential use for attention deficit hyperactivity disorder. Fasoracetam appears to agonize all three groups of metabotropic glutamate receptors and has improved cognitive function in rodent studies. It is orally bioavailable and is excreted mostly unchanged via the urine."@en . . "Fasoracetam3d.png"@en . . . . . . . . . . . . . . . . . . "Fasoracetam.svg"@en . . . "948139"^^ . . "\u30D5\u30A1\u30BD\u30E9\u30BB\u30BF\u30E0(Fasoracetam)\u306F\u3001\u30E9\u30BB\u30BF\u30E0\u7CFB\u306E\u7814\u7A76\u7528\u8A66\u85AC\u3067\u3042\u308B\u3002\u30B9\u30DE\u30FC\u30C8\u30C9\u30E9\u30C3\u30B0\u3068\u3057\u3066\u306E\u4F5C\u7528\u3092\u6301\u3064\u3068\u8003\u3048\u3089\u308C\u308B\u304C\u3001\u8133\u8840\u7BA1\u6027\u8A8D\u77E5\u75C7\u306E\u81E8\u5E8A\u8A66\u9A13\u3067\u306F\u5341\u5206\u306A\u52B9\u679C\u304C\u898B\u3089\u308C\u305A\u3001\u305D\u306E\u5F8C\u306F\u6CE8\u610F\u6B20\u9665\u30FB\u591A\u52D5\u6027\u969C\u5BB3(ADHD)\u306E\u6CBB\u7642\u7528\u9014\u3067\u7814\u7A76\u3055\u308C\u305F\u3002 \u30CD\u30BA\u30DF\u3067\u306F\u30013\u7A2E\u985E\u5168\u3066\u306E(mGluR)\u306B\u5BFE\u3057\u3066\u4F5C\u52D5\u3057\u3001\u8A8D\u77E5\u6A5F\u80FD\u3092\u6539\u5584\u3057\u305F\u3002\u7D4C\u53E3\u6442\u53D6\u53EF\u80FD\u3067\u3001\u307B\u307C\u5909\u5316\u306E\u306A\u3044\u307E\u307E\u5C3F\u304B\u3089\u6392\u51FA\u3055\u308C\u308B\u3002 \u65E5\u672C\u65B0\u85AC\u306E\u7814\u7A76\u8005\u304C\u767A\u898B\u3057\u3001\u8133\u8840\u7BA1\u6027\u8A8D\u77E5\u75C7\u306E\u7B2CIII\u76F8\u81E8\u5E8A\u8A66\u9A13\u307E\u3067\u884C\u308F\u308C\u305F\u304C\u3001\u52B9\u679C\u304C\u4E0D\u8DB3\u3057\u3066\u3044\u305F\u305F\u3081\u3001\u7834\u68C4\u3055\u308C\u305F\u3002 Hakon Hakonarson\u304C\u7387\u3044\u308B\u306E\u7814\u7A76\u8005\u304CADHD\u306E\u6CBB\u7642\u7528\u9014\u306E\u7814\u7A76\u3092\u884C\u3063\u3066\u3044\u308B\u3002Hakonarson\u306F\u3001neuroFix Therapeutics\u3068\u547C\u3070\u308C\u308B\u4F1A\u793E\u3092\u7ACB\u3061\u4E0A\u3052\u3001\u65E5\u672C\u65B0\u85AC\u306E\u81E8\u5E8A\u30C7\u30FC\u30BF\u3082\u53D6\u5F97\u3057\u3066\u3001\u3053\u306E\u7528\u9014\u306E\u305F\u3081\u306B\u5E02\u5834\u306B\u51FA\u3059\u3053\u3068\u3092\u76EE\u6307\u3057\u305F\u3002neuroFix\u306F2015\u5E74\u306BMedgenics\u306B\u8CB7\u53CE\u3055\u308C\u3001\u3055\u3089\u306BMedgenics\u306F2016\u5E74\u306BAevi Genomic Medicine\u3068\u6539\u540D\u3057\u305F\u3002mGluR\u306B\u5909\u7570\u3092\u6301\u3064\u601D\u6625\u671F\u306EADHD\u60A3\u8005\u306B\u5BFE\u3059\u308B\u81E8\u5E8A\u8A66\u9A13\u306F2016\u5E74\u306B\u59CB\u307E\u3063\u305F\u3002"@ja . . . "(5R)-5-(Piperidine-1-carbonyl)pyrrolidin-2-one"@en . . "\u30D5\u30A1\u30BD\u30E9\u30BB\u30BF\u30E0(Fasoracetam)\u306F\u3001\u30E9\u30BB\u30BF\u30E0\u7CFB\u306E\u7814\u7A76\u7528\u8A66\u85AC\u3067\u3042\u308B\u3002\u30B9\u30DE\u30FC\u30C8\u30C9\u30E9\u30C3\u30B0\u3068\u3057\u3066\u306E\u4F5C\u7528\u3092\u6301\u3064\u3068\u8003\u3048\u3089\u308C\u308B\u304C\u3001\u8133\u8840\u7BA1\u6027\u8A8D\u77E5\u75C7\u306E\u81E8\u5E8A\u8A66\u9A13\u3067\u306F\u5341\u5206\u306A\u52B9\u679C\u304C\u898B\u3089\u308C\u305A\u3001\u305D\u306E\u5F8C\u306F\u6CE8\u610F\u6B20\u9665\u30FB\u591A\u52D5\u6027\u969C\u5BB3(ADHD)\u306E\u6CBB\u7642\u7528\u9014\u3067\u7814\u7A76\u3055\u308C\u305F\u3002 \u30CD\u30BA\u30DF\u3067\u306F\u30013\u7A2E\u985E\u5168\u3066\u306E(mGluR)\u306B\u5BFE\u3057\u3066\u4F5C\u52D5\u3057\u3001\u8A8D\u77E5\u6A5F\u80FD\u3092\u6539\u5584\u3057\u305F\u3002\u7D4C\u53E3\u6442\u53D6\u53EF\u80FD\u3067\u3001\u307B\u307C\u5909\u5316\u306E\u306A\u3044\u307E\u307E\u5C3F\u304B\u3089\u6392\u51FA\u3055\u308C\u308B\u3002 \u65E5\u672C\u65B0\u85AC\u306E\u7814\u7A76\u8005\u304C\u767A\u898B\u3057\u3001\u8133\u8840\u7BA1\u6027\u8A8D\u77E5\u75C7\u306E\u7B2CIII\u76F8\u81E8\u5E8A\u8A66\u9A13\u307E\u3067\u884C\u308F\u308C\u305F\u304C\u3001\u52B9\u679C\u304C\u4E0D\u8DB3\u3057\u3066\u3044\u305F\u305F\u3081\u3001\u7834\u68C4\u3055\u308C\u305F\u3002 Hakon Hakonarson\u304C\u7387\u3044\u308B\u306E\u7814\u7A76\u8005\u304CADHD\u306E\u6CBB\u7642\u7528\u9014\u306E\u7814\u7A76\u3092\u884C\u3063\u3066\u3044\u308B\u3002Hakonarson\u306F\u3001neuroFix Therapeutics\u3068\u547C\u3070\u308C\u308B\u4F1A\u793E\u3092\u7ACB\u3061\u4E0A\u3052\u3001\u65E5\u672C\u65B0\u85AC\u306E\u81E8\u5E8A\u30C7\u30FC\u30BF\u3082\u53D6\u5F97\u3057\u3066\u3001\u3053\u306E\u7528\u9014\u306E\u305F\u3081\u306B\u5E02\u5834\u306B\u51FA\u3059\u3053\u3068\u3092\u76EE\u6307\u3057\u305F\u3002neuroFix\u306F2015\u5E74\u306BMedgenics\u306B\u8CB7\u53CE\u3055\u308C\u3001\u3055\u3089\u306BMedgenics\u306F2016\u5E74\u306BAevi Genomic Medicine\u3068\u6539\u540D\u3057\u305F\u3002mGluR\u306B\u5909\u7570\u3092\u6301\u3064\u601D\u6625\u671F\u306EADHD\u60A3\u8005\u306B\u5BFE\u3059\u308B\u81E8\u5E8A\u8A66\u9A13\u306F2016\u5E74\u306B\u59CB\u307E\u3063\u305F\u3002"@ja . . "changed"@en . . . . . . . "changed"@en . "-5"^^ . . . "100"^^ . . "Fasoracetam (NS-105, 5-oxo-D-prolinepiperidinamide monohydrate) es una sustancia qu\u00EDmica en investigaci\u00F3n de la familia de los racetam.\u200B Este nootropico est\u00E1 siendo estudiado para tratar el S\u00EDndrome de Atenci\u00F3n con hiperactividad y est\u00E1 en fase de pruebas desde 2015 arrojando resultados positivos.\u200B Es com\u00FAn como suplemento nutricional nootropico (que favorece las capacidades intelectuales), de venta por internet, as\u00ED como otros compuestos de la misma familia."@es . "7823"^^ . . . . . . . . . . . . . "444354364"^^ . . . . . "(5R)-5-Oxo-(D)-prolinepiperidinamide monohydrate, NS-105, AEVI-001, LAM 105, MDGN-001, NFC 1"@en . . . . . "125"^^ . .